BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 20578832)

  • 1. Generation and characterization of non-small-cell lung cancer cell lines and clones for use in the study of immunotherapy.
    Yannelli JR
    Cancer Biother Radiopharm; 2010 Jun; 25(3):269-78. PubMed ID: 20578832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of CD8 T-cell-Ifn-gamma response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma.
    Raez LE; Cassileth PA; Schlesselman JJ; Padmanabhan S; Fisher EZ; Baldie PA; Sridhar K; Podack ER
    Cancer Gene Ther; 2003 Nov; 10(11):850-8. PubMed ID: 14605671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of tumor antigens and tumor-antigen specific T cells in NSCLC patients: Correlation of the quality of T cell responses with NSCLC subtype.
    Palata O; Podzimkova Hradilova N; Mysiková D; Kutna B; Mrazkova H; Lischke R; Spisek R; Adkins I
    Immunol Lett; 2020 Mar; 219():46-53. PubMed ID: 31931024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel antigens in non-small cell lung cancer: SP17, AKAP4, and PTTG1 are potential immunotherapeutic targets.
    Mirandola L; Figueroa JA; Phan TT; Grizzi F; Kim M; Rahman RL; Jenkins MR; Cobos E; Jumper C; Alalawi R; Chiriva-Internati M
    Oncotarget; 2015 Feb; 6(5):2812-26. PubMed ID: 25739119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Responses to the Cancer Testis Antigen XAGE-1b in Non Small Cell Lung Cancer Caucasian Patients.
    Saito K; Nakayama E; Valmori D
    PLoS One; 2016; 11(3):e0150623. PubMed ID: 26937656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A different pattern of cytotoxic T lymphocyte recognition against primary and metastatic tumor cells in a patient with nonsmall cell lung carcinoma.
    So T; Takenoyama M; Ichiki Y; Mizukami M; So T; Hanagiri T; Sugio K; Yasumoto K
    Cancer; 2005 Jan; 103(1):200-8. PubMed ID: 15573370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of expression of cancer/testis antigen and down-regulation of HLA class-I in patients with stage I non-small cell lung cancer.
    Hanagiri T; Shigematsu Y; Shinohara S; Takenaka M; Oka S; Chikaishi Y; Nagata Y; Baba T; Uramoto H; So T; Yamada S
    Anticancer Res; 2013 May; 33(5):2123-8. PubMed ID: 23645764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of IL-2-dependent cytolytic T lymphocytes (CTLs) with altered TCR responses derived from antigen-dependent CTL clones.
    Gullo CA; Esser MT; Fuller CL; Lam Braciale V
    J Immunol; 1999 Jun; 162(11):6466-72. PubMed ID: 10352261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of cytotoxic T lymphocytes against autologous lung cancer cells resistant to apoptosis.
    Hiraki A; Ono T; Tanaka M; Kiura K; Ueoka H; Kawai H; Harada M; Nakayama E; Noguchi Y
    Anticancer Res; 2001; 21(4A):2561-7. PubMed ID: 11724322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer.
    Raez LE; Cassileth PA; Schlesselman JJ; Sridhar K; Padmanabhan S; Fisher EZ; Baldie PA; Podack ER
    J Clin Oncol; 2004 Jul; 22(14):2800-7. PubMed ID: 15254047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct proliferative T cell clonotypes are generated in response to a murine retrovirus-induced syngeneic T cell leukemia: viral gp70 antigen-specific MT4+ clones and Lyt-2+ cytolytic clones which recognize a tumor-specific cell surface antigen.
    Matis LA; Ruscetti SK; Longo DL; Jacobson S; Brown EJ; Zinn S; Kruisbeek AM
    J Immunol; 1985 Jul; 135(1):703-13. PubMed ID: 2582053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Derivation of tumor-specific cytolytic T-cell clones from two lung cancer patients with long survival.
    Weynants P; Thonnard J; Marchand M; Delos M; Boon T; Coulie PG
    Am J Respir Crit Care Med; 1999 Jan; 159(1):55-62. PubMed ID: 9872818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of cytotoxic T lymphocytes against human cancer cell lines using dendritic cell-tumor cell hybrids generated by a newly developed electrofusion technique.
    Imura K; Ueda Y; Hayashi T; Itoh T; Shimizu K; Tamai H; Yano Y; Naito K; Kohara J; Nakane K; Matsuura Y; Takeda A; Takeda T; Kawai K; Yamagishi H
    Int J Oncol; 2006 Sep; 29(3):531-9. PubMed ID: 16865268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
    Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
    Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful induction of tumor-specific cytotoxic T lymphocytes from patients with non-small cell lung cancer using CD80-transfected autologous tumor cells.
    Takenoyama M; Yoshino I; Eifuku R; So T; Imahayashi S; Sugaya M; Yasuda M; Inoue M; Ichiyoshi Y; Osaki T; Nagashima A; Nomoto K; Yasumoto K
    Jpn J Cancer Res; 2001 Mar; 92(3):309-15. PubMed ID: 11267941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-lived fusions of human haematological tumour cells and B-lymphoblastoid cells induce tumour antigen-specific cytotoxic T-cell responses in vitro.
    Mohamed YS; Dunnion D; Teobald I; Walewska R; Browning MJ
    Immunobiology; 2012 Jul; 217(7):719-29. PubMed ID: 22305004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.
    Schnurr M; Galambos P; Scholz C; Then F; Dauer M; Endres S; Eigler A
    Cancer Res; 2001 Sep; 61(17):6445-50. PubMed ID: 11522639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer.
    Groeper C; Gambazzi F; Zajac P; Bubendorf L; Adamina M; Rosenthal R; Zerkowski HR; Heberer M; Spagnoli GC
    Int J Cancer; 2007 Jan; 120(2):337-43. PubMed ID: 17066423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spontaneous antibody, and CD4 and CD8 T-cell responses against XAGE-1b (GAGED2a) in non-small cell lung cancer patients.
    Ohue Y; Eikawa S; Okazaki N; Mizote Y; Isobe M; Uenaka A; Fukuda M; Old LJ; Oka M; Nakayama E
    Int J Cancer; 2012 Sep; 131(5):E649-58. PubMed ID: 22109656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.